This morning I have been thinking about how this d
Post# of 148118
We have heard the reaction from Drs who play it safe and pass on using Lerolimab in this crisis, mostly because it is not FDA approved, and partially because it is not a main stream product from a mainstream company. Even with data and FDA approval, we still are not a mainstream company and the world may possibly not really pick this up. It is a worst case scenario train of thought but I don't like assuming that once the truth of this drug is out, the world will just beat a path to our door automatically.
My thought is to really look at how drugs are picked up by the media and utilized by Drs. Drs seem to obviously look at only FDA approved drugs and know about drugs through sales reps from distributors and medical journals. The sales rep channel is the one big failing of cytodyn at this point, the deal we make with a distributor is very important in my opinion. The media is certainly eager to have news of a drug that works, and they are certainly going to investigate why nobody heard of leronlimab until this data release. Why so much attention for drugs that don't work while a drug that shows promise from day one is hidden away? It will be interesting to see how this does happen.
I am assuming that cytodyn is so focused on the day to day of getting trials done, compiling the results and navigating the financial needs to support this. They, historically, are not developing a plan to make sure the world finds out in the best possible way. We have been actively doing the grassroots method of getting the word out and cytodyn has been using questionable outlets like red chip, wallstreet reporter, etc.. I really hope the IB that is going to be backing the up list and the distributor we sign a deal with take over and do there thing. I just don't want for all of us to be left scratching our heads wondering how everything went right and it is still not able to be taken seriously.